NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

PRTA

Prothena Corporation plc

Jul 11 • 04:00PM ET

6.40

Dollar change -0.17
Percentage change -2.59	%

Healthcare • Biotechnology • Ireland • NASD

Peers: VRTX BIIB ALNY IONS SRPT NBIX EXEL ACAD ARWR CLDX

| Held by: IWM VXF IWN IBB SCHA VTWO ESML DFAS DFAT VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.08	Insider Own	21.38%	Shs Outstand	53.83M	Perf Week	-0.54%
Market Cap	344.49M	Forward P/E	-	EPS next Y	-2.58	Insider Trans	-34.54%	Shs Float	42.32M	Perf Month	21.67%
Enterprise Value	-63.25M	PEG	-	EPS next Q	-1.22	Inst Own	70.17%	Short Float	10.23%	Perf Quarter	-37.62%
Income	-110.27M	P/S	2.50	EPS this Y	-70.39%	Inst Trans	-29.25%	Short Ratio	2.43	Perf Half Y	-54.77%
Sales	137.94M	P/B	0.79	EPS next Y	33.21%	ROA	-19.72%	Short Interest	4.33M	Perf YTD	-53.79%
Book/sh	8.13	P/C	0.82	EPS next 5Y	-9.84%	ROE	-23.46%	52W High	25.42 -74.82%	Perf Year	-68.95%
Cash/sh	7.76	P/FCF	-	EPS past 3/5Y	- -3.15%	ROIC	-24.76%	52W Low	4.32 48.15%	Perf 3Y	-78.38%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-12.33% 178.00%	Gross Margin	97.39%	Volatility	4.09% 6.08%	Perf 5Y	-40.07%
Dividend TTM	-	EV/Sales	-0.46	EPS Y/Y TTM	36.41%	Oper. Margin	-100.49%	ATR (14)	0.39	Perf 10Y	-87.32%
Dividend Ex-Date	-	Quick Ratio	9.00	Sales Y/Y TTM	54.55%	Profit Margin	-79.94%	RSI (14)	54.79	Recom	2.22
Dividend Gr. 3/5Y	- -	Current Ratio	9.00	EPS Q/Q	16.85%	SMA20	5.96%	Beta	-0.04	Target Price	24.29
Payout	-	Debt/Eq	0.02	Sales Q/Q	5556.00%	SMA50	1.91%	Rel Volume	0.32	Prev Close	6.57
Employees	163	LT Debt/Eq	0.02	Earnings	May 08 AMC	SMA200	-48.72%	Avg Volume	1.78M	Price	6.40
IPO	Dec 21, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	-15.46% -75.30%	Trades		Volume	569,047	Change	-2.59%

Date	Action	Analyst	Rating Change	Price Target Change
May-28-25	Downgrade	BofA Securities	Neutral → Underperform	$4
May-27-25	Downgrade	Oppenheimer	Outperform → Perform
May-27-25	Downgrade	Jefferies	Buy → Hold	$6
May-27-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Dec-20-24	Initiated	Chardan Capital Markets	Buy	$40
Jan-30-24	Downgrade	BofA Securities	Buy → Neutral	$68 → $38
Dec-12-23	Initiated	Deutsche Bank	Buy	$62
Apr-24-23	Initiated	SVB Securities	Outperform	$80
Jan-27-23	Initiated	Piper Sandler	Overweight	$94
Nov-04-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$52 → $55
Sep-28-22	Upgrade	BofA Securities	Neutral → Buy
Nov-19-21	Initiated	JMP Securities	Mkt Outperform	$77
Jun-18-21	Upgrade	BofA Securities	Underperform → Neutral	$12 → $49
Jun-08-21	Reiterated	Oppenheimer	Outperform	$45 → $54
May-26-21	Initiated	Citigroup	Buy	$39
Feb-26-21	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$14 → $28
Feb-12-21	Upgrade	Jefferies	Hold → Buy	$15 → $30
Feb-02-21	Upgrade	BTIG Research	Neutral → Buy	$29
Dec-07-20	Initiated	H.C. Wainwright	Buy	$22
Jul-09-20	Upgrade	Oppenheimer	Perform → Outperform	$16

Show Previous Ratings

Jul-04-25 01:51PM	PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects? (Zacks)
Jun-20-25 07:22AM	Prothena to lay off majority of staff; Zealand shares obesity drug data (BioPharma Dive)
Jun-18-25 04:05PM	Prothena Announces Corporate Restructuring (Business Wire)
Jun-17-25 01:30PM	Roche's Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA) (Insider Monkey)
09:16AM	Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus (TipRanks)
10:22AM	Loading…
Jun-16-25 10:22AM	Roche, waving off study failures, commits to Phase 3 trials for Parkinsons drug (BioPharma Dive) +11.42%
09:49AM	RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development (Zacks)
01:06AM	Prothenas Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease (Business Wire)
May-29-25 03:40PM	Citizens JMP Slashes Prothena (PRTA) to $29 from $78 After AFFIRM-AL Trial Fails (Insider Monkey)
May-28-25 01:55PM	Oppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from Outperform (Insider Monkey)
May-27-25 01:08PM	Jefferies Downgrades Prothena Corporation (PRTA) After Negative Trial Results (Insider Monkey) -30.40%
10:20AM	Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down (Zacks)
07:53AM	Biogen strikes RNAi deal with City; Aurion withdraws IPO (BioPharma Dive)
07:43AM	Why Is Prothena Stock Trading Lower On Tuesday? (Benzinga)
May-26-25 06:16AM	Prothenas Phase III trial for AL amyloidosis treatment misses endpoint (Clinical Trials Arena)
04:05PM	Loading…
May-23-25 04:05PM	Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint (Business Wire) -30.40%
May-09-25 01:28PM	Prothena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025 (Zacks)
08:29AM	Is Prothena Corporation plc (PRTA) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey)
May-08-25 05:50PM	Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:47PM	Prothena: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports First Quarter 2025 Financial Results and Business Highlights (Business Wire)
May-07-25 12:44PM	Prothena Q1 2025 Earnings Preview (Seeking Alpha)
May-01-25 04:05PM	Prothena to Report First Quarter 2025 Financial Results on May 8 (Business Wire) -5.22%
Apr-16-25 11:49AM	Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi (Zacks)
Feb-21-25 02:15AM	Prothena Corp PLC (PRTA) Q4 2024 Earnings Call Highlights: Strong Financial Position Amidst ... (GuruFocus.com)
Feb-20-25 05:25PM	Prothena (PRTA) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:22PM	Prothena: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights (Business Wire)
Feb-13-25 04:05PM	Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025 (Business Wire)
Dec-30-24 04:05PM	Prothena Announces Board of Directors Update (Business Wire) -6.92%
04:22PM	Loading…
Dec-19-24 04:22PM	Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease (Investor's Business Daily) +33.97%
08:09AM	Prothenas Parkinsons study fails primary endpoint despite some success (Clinical Trials Arena)
01:05AM	Roches Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinsons Disease (Business Wire)
Dec-12-24 11:30AM	Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report? (Zacks)
Nov-12-24 05:55PM	Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:56PM	Prothena: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports Third Quarter 2024 Financial Results and Business Highlights (Business Wire)
Nov-05-24 04:05PM	Prothena to Report Third Quarter 2024 Financial Results on November 12 (Business Wire) +8.71%
Oct-29-24 12:00PM	Prothena (PRTA) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
04:48AM	Strength Seen in Prothena (PRTA): Can Its 15.0% Jump Turn into More Strength? (Zacks)
Oct-18-24 03:01PM	State Street Corp's Strategic Reduction in Prothena Corp PLC Holdings (GuruFocus.com)
Sep-27-24 04:05PM	Prothena Announces Leadership Team Updates (Business Wire) -16.56%
Aug-29-24 04:05PM	Prothena to Participate in Upcoming Healthcare Conferences (Business Wire)
Aug-19-24 12:00PM	What Makes Prothena (PRTA) a New Buy Stock (Zacks)
Aug-18-24 12:28AM	Prothena Corporation plc (PTRA): Positioning Among Top Debt-Free Stocks (Insider Monkey)
Aug-17-24 08:22AM	7 Best Debt Free Stocks To Buy (Insider Monkey)
Aug-09-24 09:16AM	Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues (Zacks)
Aug-08-24 06:40PM	Prothena (PRTA) Q2 Earnings and Revenues Beat Estimates (Zacks)
05:33PM	Prothena: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports Second Quarter 2024 Financial Results and Business Highlights (Business Wire)
Aug-01-24 04:05PM	Prothena to Report Second Quarter 2024 Financial Results on August 8 (Business Wire) -5.20%
Jul-25-24 10:02AM	Prothena (PRTA) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jun-24-24 08:48AM	Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last? (Zacks)
Jun-11-24 04:07PM	Eli Lilly Seesaws On FDA Win, And Pushes Alzheimer's Stocks Prothena, Eisai Lower (Investor's Business Daily)
12:20PM	Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win (Investor's Business Daily)
Jun-07-24 11:30AM	Why Is Prothena (PRTA) Down 1.5% Since Last Earnings Report? (Zacks)
May-29-24 10:26AM	Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate (Zacks)
08:46AM	BMS stakes $80m on Prothenas neurodegenerative candidate (Pharmaceutical Technology)
May-28-24 04:05PM	Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration (Business Wire)
May-09-24 11:52AM	Prothena (PRTA) Q1 Earnings Miss Estimates on Higher R&D Expenses (Zacks)
May-08-24 10:56PM	PRTA Stock Earnings: Prothena Corp Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:10PM	Prothena (PRTA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
05:14PM	Prothena: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports First Quarter 2024 Financial Results and Business Highlights (Business Wire)
May-01-24 04:05PM	Prothena to Report First Quarter 2024 Financial Results on May 8 (Business Wire) +5.31%
Apr-25-24 10:01AM	Earnings Preview: Prothena (PRTA) Q1 Earnings Expected to Decline (Zacks)
Apr-15-24 04:05PM	Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma (Business Wire)
Mar-28-24 08:00AM	Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback (Investor's Business Daily)
Mar-05-24 04:05PM	Prothena to Participate in Upcoming Healthcare Conferences (Business Wire)
Mar-04-24 04:05PM	Prothena Appoints David Ford to Newly Created Chief People Officer Position (Business Wire)
Feb-21-24 04:05PM	Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate (Business Wire)
Feb-16-24 01:33PM	Prothena (PRTA) Q4 Earnings Miss Estimates on Higher R&D Expense (Zacks)
10:33AM	Prothena Corporation plc (NASDAQ:PRTA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-15-24 04:50PM	Prothena: Q4 Earnings Snapshot (Associated Press Finance)
04:48PM	Prothena Corp PLC (PRTA) Reports 2023 Financial Results and Provides 2024 Outlook (GuruFocus.com)
04:05PM	Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights (Business Wire)
Feb-08-24 04:05PM	Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024 (Business Wire)
Jan-24-24 11:02PM	Prothena Corp PLC Chief Accounting Officer Sells 5,000 Shares (GuruFocus.com)
Jan-10-24 12:06PM	Prothena's (PRTA) Update on Pipeline Progress Disappoints (Zacks) -9.46%
05:38AM	Prothena (PRTA) Surges 12.3%: Is This an Indication of Further Gains? (Zacks)
Jan-08-24 08:30AM	Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs (Business Wire) -13.23%
Dec-21-23 09:01AM	Prothena Corp PLC Chief Accounting Officer Sells Company Shares (GuruFocus.com)
Dec-17-23 05:41AM	These 3 Biotech Stocks Have Strong Upside Potential, Says Deutsche Bank (TipRanks)
Dec-01-23 11:05AM	Insider Sell Alert: Karin Walker of Prothena Corp PLC Cashes Out 5,000 Shares (GuruFocus.com) +7.09%
Nov-29-23 08:35AM	Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks (Investor's Business Daily)
Nov-20-23 06:00AM	FOCUS-Researchers return to Alzheimer's vaccines, buoyed by recent drug success (Reuters)
Nov-17-23 01:35PM	Prothena (PRTA) Pipeline Shows Promise in a Tough AD Market (Zacks)
08:15AM	Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning (Investor's Business Daily)
Nov-03-23 11:34AM	Prothena (PRTA) Q3 Earnings Beat on Collaboration Revenue Hike (Zacks) +7.41%
Nov-02-23 07:03PM	Prothena Corp PLC (PRTA) Reports Q3 2023 Financial Results (GuruFocus.com)
06:25PM	Prothena (PRTA) Beats Q3 Earnings and Revenue Estimates (Zacks)
05:24PM	Prothena: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports Third Quarter 2023 Financial Results and Business Highlights (Business Wire)
Oct-30-23 10:00AM	Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-26-23 04:09PM	Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's Treatment (Investor's Business Daily) -14.62% +5.52%
04:05PM	Prothena to Report Third Quarter 2023 Financial Results on November 2 (Business Wire)
10:02AM	Prothena (PRTA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
05:02AM	Insider Sell: Karin Walker Sells 5,000 Shares of Prothena Corp PLC (GuruFocus.com)
Oct-18-23 11:20AM	5 Biotech Stocks Set to Outpace Q3 Earnings Estimates (Zacks)
Oct-17-23 07:57AM	Prothena (PRTA) Soars 18.7%: Is Further Upside Left in the Stock? (Zacks) -9.92%

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm's clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
EcoR1 Capital, LLC	10% Owner	May 02 '25	Sale	8.36	3,317,938	27,744,929	8,266,342	May 06 07:06 PM
EcoR1 Capital, LLC	10% Owner	May 06 '25	Sale	7.64	1,984,053	15,164,712	5,304,596	May 06 07:06 PM
EcoR1 Capital, LLC	10% Owner	May 05 '25	Sale	8.11	977,693	7,930,166	7,288,649	May 06 07:06 PM
SCULLY WILLIAM P	10% Owner	Jan 14 '25	Buy	12.79	100,000	1,279,040	735,993	May 02 10:29 AM
SCULLY WILLIAM P	10% Owner	Dec 18 '24	Buy	13.93	73,436	1,022,670	1,297,693	May 02 10:29 AM
SCULLY WILLIAM P	10% Owner	Dec 31 '24	Buy	13.01	32,000	416,393	650,193	May 02 10:29 AM
SCULLY WILLIAM P	10% Owner	Dec 20 '24	Buy	15.91	2,000	31,813	618,693	May 02 10:29 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PRTA

Prothena Corporation plc

Upgrade your FINVIZ experience